| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702721 | Urologic Oncology: Seminars and Original Investigations | 2017 | 9 Pages |
Abstract
Carriers of GSTM1-null and GSTP1-variant genotypes are in increased risk of RCC development. On the contrary, GSTM1-null genotype is associated with favorable postoperative prognosis in ccRCC. The possible molecular mechanism underlying the role of GSTM1 protein in RCC progression might be the presence of GSTM1:ASK1 protein-protein interaction. Hence, determination of GSTM1-genotype might serve as a valuable indicator in both RCC risk assessment and postoperative prognosis.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Vesna M. M.D., Tatjana P. M.D., Ph.D., Tatjana D. M.D., Ph.D., Gordana M. M.D., Ph.D., Ana R. M.D., Ph.D., Sanja M. M.D., Ph.D., Marija G. M.D., Ph.D., Sonja R. M.D., Ph.D., Dejan P. M.D., Ph.D., Tanja M. M.Sc., Zoran M. M.D., Ph.D., Marija S. M.D.,